scholarly journals Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

2021 ◽  
Vol 22 (12) ◽  
pp. 6288
Author(s):  
Edouard Dantoing ◽  
Nicolas Piton ◽  
Mathieu Salaün ◽  
Luc Thiberville ◽  
Florian Guisier
Keyword(s):  
Lung Cancer ◽  
Tumor Microenvironment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Molecular Mechanisms ◽  
Standard Of Care ◽  
Small Cell ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Oncogenic Driver

Anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for stage III-IV non-small cell lung cancer (NSCLC) over the past decade. Patient selection is usually based on PD-L1 expression by tumor cells and/or tumor mutational burden. However, mutations in oncogenic drivers such as EGFR, ALK, BRAF, or MET modify the immune tumor microenvironment and may promote anti-PD1/PD-L1 resistance. In this review, we discuss the molecular mechanisms associated with these mutations, which shape the immune tumor microenvironment and may impede anti-PD1/PD-L1 efficacy. We provide an overview of the current clinical data on anti-PD1/PD-L1 efficacy in NSCLC with oncogenic driver mutation.

Systemic and Radiation Therapy Approaches for Locally Advanced Non–Small-Cell Lung Cancer

2022 ◽  
Author(s):  
Kristin A. Higgins ◽  
Sonam Puri ◽  
Jhanelle E. Gray
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Standard Of Care ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Concurrent Chemoradiation ◽  
Driver Mutations ◽  
Small Cell Lung

The treatment for locally advanced non–small-cell lung cancer has changed dramatically over the past several years, with consolidative immunotherapy after concurrent chemoradiation becoming the new standard of care. Five-year survival outcomes have substantially improved with this approach. Despite these advances, further improvements are needed as the majority of patients ultimately develop progression of disease. The next-generation immunotherapy trials are currently being conducted that include approaches such as concurrent immunotherapy and addition of other therapeutic agents in the concurrent and consolidative settings. Specific unmet needs continue to exist for patients who develop disease progression after concurrent chemoradiation and immunotherapy, as well as defining the best treatment for patients with driver mutations. Future directions also include refinement of radiation techniques to reduce toxicities as much as possible, as well as the use of circulating tumor DNA in the surveillance setting. The current scientific landscape shows promising approaches that may further improve outcomes for patients with locally advanced non–small-cell lung cancer.

scholarly journals Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients

Oncotarget ◽  
2015 ◽  
Vol 6 (33) ◽  
pp. 34300-34308 ◽  
Author(s):  
Rui Wang ◽  
Yang Zhang ◽  
Yunjian Pan ◽  
Yuan Li ◽  
Haichuan Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Comprehensive Investigation ◽  
Lung Cancer Patients ◽  
Oncogenic Driver

scholarly journals Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages

2013 ◽  
Vol 24 (5) ◽  
pp. 1319-1325 ◽  
Author(s):  
J.X. Zhou ◽  
H. Yang ◽  
Q. Deng ◽  
X. Gu ◽  
P. He ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Clinical Stages ◽  
Oncogenic Driver

scholarly journals Oncogenic Driver Mutations in Chinese Non-Small Cell Lung Cancer (NSCLC)

2012 ◽  
Vol 23 ◽  
pp. ix389-ix390
Author(s):  
J. He ◽  
H. Yang ◽  
Q. Deng ◽  
P. He ◽  
J. Jiang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Oncogenic Driver

scholarly journals Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective

2019 ◽  
Vol 26 (4) ◽  
Author(s):  
D. G. Bebb ◽  
J. Agulnik ◽  
R. Albadine ◽  
S. Banerji ◽  
G. Bigras ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Molecular Subtype ◽  
Treatment Options ◽  
Standard Of Care ◽  
Small Cell ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Ros1 Rearrangement

The ROS1 kinase is an oncogenic driver in non-small-cell lung cancer (NSCLC). Fusion events involving the ROS1 gene are found in 1%–2% of NSCLC patients and lead to deregulation of a tyrosine kinase–mediated multi-use intracellular signalling pathway, which then promotes the growth, proliferation, and progression of tumour cells. ROS1 fusion is a distinct molecular subtype of NSCLC, found independently of other recognized driver mutations, and it is predominantly identified in younger patients (<50 years of age), women, never-smokers, and patients with adenocarcinoma histology.    Targeted inhibition of the aberrant ros1 kinase with crizotinib is associated with increased progression-free survival (PFS) and improved quality-of-life measures. As the sole approved treatment for ROS1-rearranged NSCLC, crizotinib has been demonstrated, through a variety of clinical trials and retrospective analyses, to be a safe, effective, well-tolerated, and appropriate treatment for patients having the ROS1 rearrangement.    Canadian physicians endorse current guidelines which recommend that all patients with nonsquamous advanced NSCLC, regardless of clinical characteristics, be tested for ROS1 rearrangement. Future integration of multigene testing panels into the standard of care could allow for efficient and cost-effective comprehensive testing of all patients with advanced NSCL. If a ROS1 rearrangement is found, treatment with crizotinib, preferably in the first-line setting, constitutes the standard of care, with other treatment options being investigated, as appropriate, should resistance to crizotinib develop.

scholarly journals Oncogenic driver mutations in non-small cell lung cancer: Past, present and future

2021 ◽  
Vol 12 (4) ◽  
pp. 217-237
Author(s):  
Mathieu Chevallier ◽  
Maxime Borgeaud ◽  
Alfredo Addeo ◽  
Alex Friedlaender
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Driver Mutations ◽  
Small Cell Lung ◽  
Oncogenic Driver
Sign in / Sign up

Export Citation Format

Share Document